Advances in Personalized DNA Vaccine Platform Drive Enhanced Clinical Outcomes
9:30 am - Wednesday 2nd December 2026
- Reviewing clinical data in advanced liver cancer and adjuvant GBM patients demonstrating the safety, immunogenicity, and efficacy of Geneos’ personalized vaccine platform
- Exploring how patient-specific neoantigen targeting can enhance anti-tumor immunity across multiple solid tumor indications
- Discussing the implications of these findings for personalized cancer vaccines in advanced and adjuvant cancer treatment settings
